Most medical breakthroughs in the United States take around 17 years to be developed, approved, and implemented. If this timeframe can be shortened, more lives can be saved and more medical institutions can improve their methods. Julio Martinez-Clark is committed to speeding up medical innovations by bringing them over to other countries with more medical-friendly regulations. Joining Zach Gurick, he shares how their global network at bioaccess® fast-tracks clinical trials and research, allowing for medical innovations to roll out much faster. Julio also presents the latest cutting-edge breakthroughs they have supported that allow for more precise and effective treatments.
The information presented in Fully Alive is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before making changes to your health regimen. Guests’ opinions are their own and do not necessarily reflect those of the podcast host, production team, or sponsors.
Watch the episode here
Listen to the podcast here
Speeding Up Medical Breakthroughs With Julio Martinez-Clark
Fast-Tracking Clinical Trials With Julio Martinez-Clark Of bioaccess®
Welcome back to the show, where we are unlocking the secrets to your healthier, happier, longer life. Our guest is someone who’s not only shaping the future of longevity but is also reimagining where that future is being built. My guest is Julio Martinez-Clark. He’s the founder and CEO of a company called Bioaccess®, which is a pioneering company that’s been breaking down the traditional barriers to medical innovation for over a decade.
Julio has helped position regions like Latin America and Australia as major players in the global clinical research ecosystem. He’s transforming how medtech, biopharma, and something called radiopharma breakthroughs come to life, bringing more cost-effective, ethically sound clinical trials to places that have often been overlooked. Through his work, he’s not only accelerating the time it takes for lifesaving therapies to reach the market but also improving healthcare access for underserved populations around the world.
In our conversation, we’re going to dive into some of the most cutting-edge companies and innovations in the longevity space, from gene therapies to AI-empowered dentists to brain computer interfaces. Julio shares what he’s most excited about for the future of human health and performance. This one is full of insight, inspiration, and a refreshing global perspective. Let’s get into it. Here’s my conversation with Julio Martinez-Clark.
Julio, thank you so much for being on the show. It’s such a privilege and an honor to have you with us. I’m really looking forward to this conversation. I’m excited for our readers to hear from you. You have this amazing front row seat to so many medical breakthroughs and cutting edge technologies, and things that are coming in on the horizon in the world of medicine and advanced therapies, and things like that. I’m excited to dive into a few of those things and help our readers and myself even see the world through your eyes for a few minutes here. Thank you so much for joining us, and thanks for being with us.
My pleasure, Zach. Thanks for having me here. I look forward to the conversation.
You’re the CEO and founder of a company called Bioaccess®. Maybe just give us a little bit of background. You and I were just talking before this about the problem in the world that you’re solving for, but how did you end up being the CEO of Bioaccess®? Tell us a little bit about the company and what you’re doing.
The audience can tell by my accent that I was born and raised in Latin America and South America, specifically in Colombia. I left Colombia with my brother Pedro about twenty years ago, or more actually, and it depends on when you start counting. Myself, I went to University in Bogota, did intellectual engineering. I worked for a couple of global telecom and networking companies in Boston.
I got my MBA in Boston as well. The genesis of Bioaccess® and the problem that we’re solving today is Pedro, my brother. Pedro trained as a cardiologist and is also an interventional cardiologist at Harvard Medical School in Boston. He trained at the Beth Israel Medical Center. After that, he moved to Miami. He became a professor at the University of Miami, and he worked with one of the top thirders in interventional cardiology, Dr. William O’Neill. O’Neill is a block star in interventional cardiology. Pedro was very fortunate to work alongside O’Neill on medical innovations.
They developed patents together. They wrote many articles and top journals, did some extraordinary advancements in interventional cardiology. They pioneered structural heart techniques, etc. They became pretty famous in the medical innovation ecosystem in the US, more specifically in the cardiovascular space. A lot of medical device companies were seeking their help in the development of advanced cardiovascular technologies. They started working with these companies on the preclinical animal and cadaver studies needed to develop these technologies, and also in the clinical human studies needed to develop these technologies.
They quickly realized, Zach, that the companies developing these technologies face a wall in the United States because of the complexity of the healthcare system, because of the bureaucracy of the hospital systems. It takes too long to get these first in human trials approved to validate the safety and efficacy of these technologies. They traveled with these companies overseas.
They went to Eastern Europe, they went to Australia, they went to Latin America. They saw the struggle that these American companies face when they are ready to embark on a first-in-human trial journey, which is a major undertaking. They usually go overseas because of the complexities that I just described in the United States, and also the costs associated with doing these trials in the country.
They need somebody to guide them, to help them find these hospitals overseas that have the right patient population that they need. That’s the void that we feel at Bioaccess®. We solve that problem by accelerating the time to get a clinical trial approved for these startup companies, more specifically in Latin America, although we also have expanded to other parts of the world, Eastern Europe, Australia, but our focus has traditionally been in Latin America.
You and I were just talking about on average, a typical new technology or medication typically takes about seventeen years and costs several hundred million dollars to get approval on average. If we have a brand new breakthrough or something that’s available to us now, it’s been developed for potentially seventeen years. The technology that we’re getting in our healthcare system today is almost two decades old at this point.
It’s not the best technology. We’re not getting these breakthroughs. If we had a new breakthrough, we’re not going to be able to use that for seventeen years on average. Many of those won’t make it because of the $300 million price tag that comes along with it. You’re solving that issue by creating these overseas trials, which can then speed up the process significantly and lower the cost. When they bring it back to the US, now they’re much further down the process, right?
Exactly. Of course, money is important to them because they have limited resources. These are not multinational companies. These are three guys that saw an innovation at a university and they decided to create a company, three entrepreneurs, usually 3 to 5 people. They built the company, they get all the advisors, they raise some funds, a few million dollars, and money is limited, and time is of the essence because when you have investors, you have to give them a return at a certain time.
There’s a plan. Investors are reading down your neck to get results. You cannot really just wait for the FDA to approve or for a hospital system to approve these studies. You have to find places where you can get these approvals really fast and predictable. If I submit today, I know I’m going to get approval in a month. I mean, something like that. If I submit XYZ documents, that’s what I need, and then I’m going to get approval.
They need predictability and past approval timelines, and that’s the problem that we solved. The burn rate of these companies is very high. The burn rate for a startup can be anywhere between $100,000 to $300,000 a month, paying employees, paying advisors, fees, etc. The salaries of these people, these are professionals, highly skilled professionals, experts in the field, and they cannot really wait for the FDA to get approvals, or wait a year or 2 or 3. They need fast access to patients, and they usually go overseas for that.
Why Medical Breakthroughs In The US Take So Long
If something takes about seventeen years in the US, working with Bioaccess®, how much can you speed up that process?
Let’s start with why it takes about seventeen years. There are different phases in that seventeen-year span that we just discussed. Of course, the preclinical phase is really important. That’s animal studies and caliber studies. The model that you need to get ready for the human phase of development. We get involved in that second phase, not in the first phase.
When the company is ready for that second phase of clinical validation, that’s where we come in and we can shave probably 3 to 5 years for a company if we bring them to a friendly country, like the ones in Latin America or Eastern Europe or Australia that have very friendly regulations and are open for the clinical trial business. At the end, they see this as a way to impact their local economies.
Clinical trials bring so much transfer of knowledge. It benefits patients and also brings money to the local economy. These countries are very open and friendly to bring this industry in. I can pick up the phone and call a regulator in a country in Central America and have a pre-submission meeting just before Monday. We can get approval in less than 30 days.
You’re significantly speeding up the process and bringing these things to fruition much quicker.
Also, Zach, it’s important to mention that the conversation is centering around clinical trials, clinical validation. However, there are companies that are looking at places overseas to start commercializing first. In other words, because they don’t want to wait those seventeen years, if they can get a commercial approval to sell a product in South America.
Before the company sells the product in the United States, the technology is already accessible. It’s already in the market for patients in South America. American patients who are willing to fly and have access to these advanced technologies overseas, because they got approved faster. There are many examples of this.
There are many technologies in Europe that are already approved by the European community, but it’s not the union, but they are not approved in the United States yet. It will probably be seventeen years before the FDA approves these technologies for many reasons. Bureaucracy, the queue is too long, money, for whatever reason. These technologies are already available to patients overseas and are not yet available to patients in the United States.
Stem cells are a good example. I know there are a lot of places where you can go to Cabo or the Caribbean, Bahamas, places like that, and have stem cell treatments, which you cannot get in the US yet. Now it’s starting to open up like here in Florida, just as of July 1st of 2025. It’s a little more open and friendly. That’s a good example.
It benefits the patients because they have now access to these technologies overseas, and also benefits the company because they can start generating revenue to fund the US clinical trials needed to comply with FDA regulations.
Exploring The Brain-Computer Interface (BCI)
That makes a ton of sense. I’d love to maybe dive into a few of these breakthroughs that you’re seeing, because you have, like I said, a front row seat to all of these exciting new innovations and things like that. We talked about a few of them when we met earlier, but maybe you could tell us about some that you’re most excited about. There was one. Maybe to start with, you told me about this AXOFT, I believe it is, the Brain Computer Interface. Maybe just tell us a little bit about, first of all, what is a BCI, Brain-Computer Interface, and then what this company, AXOFT, is doing that is so remarkable?
I think everybody knows about the Neuralink device that Elon Musk is developing. It’s been in the news for the past five years or so, and I think they just completed their third patient or something like that. One of the reasons why it’s taking so long is that the trial is being conducted in the United States. AXOFT is a company that is a spin-off of Harvard University Labs. PhD students develop this brain-computer Interface similar to the Neuralink that gets implanted in your brain and can read the electrical signals that are generated when you think about something.
It’s like science fiction. It reads electrical signals and can execute some commands based on those signals. It can understand the language of those electrical signals or the human language because what you think is replicated in an electrical signal that the brain-computer interface reads and acts on, because it has an interface with the exterior world. You can type it on a computer just by thinking about what you want to type, and the computer will type something like that. This is a new trend.
It started with Neuralink, it was pioneered by Neuralink, but many companies are developing similar technologies in that same space. The BCI, brain-computer interface space, is growing exponentially. It’s one of the fastest-growing areas in medical innovation. To answer your question, we did this study in Panama. We have done, I think, about four patients already in Panama, and the results have been phenomenal. These results are helping the company refine the product, the prototype so that we can keep innovating and benefiting more patients.
If I go to the website, AXOFT, it’s just like a little piece of fabric, almost, it has these little wires in it. That gets implanted in your brain. I just think about something, and the computer does it for me. I’m just going to be able to think about something essentially, and then it’s going to get connected to the internet and searched up. If I’m Googling something now or using ChatGPT, I’ll just be able to think and have access to the world’s knowledge base.
That will open up a new frontier for human evolution because we don’t depend on a physical cell phone or a physical computer to do something, to interact with that world. We’re just going to think about it, and that’s it. The cell phone will eventually disappear.
It’s funny. I was telling my fifteen-year-old son about this. He’s like, “I could dominate the SAT and all my tests.” “Yeah. I think we’re going to have to figure out a new way to test your mental ability in the future.”
There’s been a few movies that in the past probably twenty years, there’s been a few movies that have predicted this evolution that we have today with brain computer interfaces.
It’s amazing. This is happening currently. We’re not that far away from this being commercialized. In your best guess, what prediction or timeline do you see?
For a medical device company like AXOFT to commercially be have a commercial product in the market, I think it will take them seven years or so. It’s also important, I mean, from the point they are now, and there’s probably been seven years of development that we don’t know about. From the point they are now, where they just validated the technology on humans, then the ride is a little faster.
Why? It’s because that pivotal moment of validation in humans makes the company more valuable. It raises the valuation of the company because the technology was already a risk for investors, and for the readers, it’s important to emphasize that these companies are created to be sold. They are sold for $300 million, $600 million, a billion dollars to larger companies like Medtronic, Boston Scientific, Johnson & Johnson, or big pharma, Merck, Pfizer, and Novartis. That’s how the big companies innovate.
That’s how they have very competitive and innovative products in their portfolio, and they can remain in the market with technologies that hospitals will want to buy because they’re in the business of selling medical innovation. They need to buy companies like Aesop that already they risk the process of developing these technologies, and they buy them for large amounts, as I said, and everybody’s happy, and the technology is already in the market. These large players have the resources to do these large trials that are needed or that are required by the FDA to get the approval in the United States.
Seven years from now, I mean, we’re not talking about 20 years or 30, 50 years, 100 years. We’re talking about 5 to 7 years from now. This is going to be something that’s commercial. We’re living in an exciting time. Like this is happening. As you said, it feels like science fiction, and it’s going to rapidly change human evolution, as you mentioned. That’s amazing, exciting.
How Gene Therapy And Editing Work
Maybe we could talk a little bit, maybe about another one that you mentioned called the gene therapy, gene editing therapy, Libella. You had said before, it was a pay-to-play thing, like a million dollars per person. They would edit your genes to lengthen your telomeres and potentially extend your lifespan that way. Could you tell us a little bit about that? I know that company’s struggling, maybe a little bit right now, but tell us about that technology.
There is the Nobel Prize. I think the winner was a doctor called Elizabeth Blackwell, something like that, a few years ago, about this. You need to pick up from the work of several researchers to come up with an innovation. Nobody does this alone. Dr. William Andrews is one of the pioneers in this gene therapy technology. There’s another company called BioViva, and Liz Parrish. She is very popular in this space of regenerative medicine and longevity.
Liz Parrish and Dr. Bill Andrews have been developing this telomere lengthening innovation or technology treatment that used to cost many hundreds of thousands of dollars, as you said, but now the advancement in production and newer techniques. When I first started working with this company, the name of Dr. Andrews’ company, Sierra Sciences, but they created another company, a spin-off of Sierra Sciences, called Libella Gene Therapy, which is the company that I worked with in their trials in South America.
That company, as you said, struggled a little bit because of funding, and it disappeared. It was terminated, it was liquidated. Dr. Andrews is still around in Sierra Sciences. They’re looking for investors and partners to advance this gene therapy technology. By the way, I just met with him because we’re still in conversations to see how we can help them develop this because it is something that humanity needs, which basically is a cheaper way than the almost a million-dollar treatment that we discussed before.
It’s now down to just probably $100,000 because the production cost is so low now, because of these newer techniques, that it’s going to be easier to develop and to commercialize because the price point has come down significantly. It will have more impact on society because it will be at a lower cost, and more people can afford it. The essence, the theory is that telomeres are the culprits for how we age. It’s a scientific discussion that I want to get into details.
The idea is that telomeres are part of our gene map. Telomeres have been shown in animal studies that when telomeres get shorter, you start showing the signs of aging, and you develop diseases like cancer, cardiovascular diseases. We all get all these diseases because we get older. What if aging were a disease? That is the change of paradigm that we’re seeing now.
Before that, not even the FDA was recognizing aging as a disease. If we look at our makeup at a similar level, aging is really a disease. It’s being now recognized as a disease. If we treat aging as a disease, we can now understand the causes of aging and then treat those causes. Telomere lengthening is one of those treatments that have been proven, at least in animal models, to extend our lifespan.
Just for our readers to understand a little bit, as our telomeres shorten, it really regulates how often or how many times our cells can replicate. Once they get down below a certain, those telomeres get too short, then our cells no longer replicate, then we get senescent cells, then those turn into zombie cells, and it causes all the problems of aging, like you mentioned. If we can lengthen those telomeres, then those cells can continue replicating indefinitely.
You’re talking about actually editing our genes so that our telomeres are lengthened instead of shortened over time. Essentially, our cells just continue replicating indefinitely, and therefore, we don’t age. That’s what you’re talking about. I’m somewhat familiar with Dr. Bill Andrews and Sierra Sciences and the amazing work that he’s doing, and you mentioned Liz Parrish as well. If we can solve that issue, and it sounds like they’re doing it, and for a hundred thousand dollars a person, you could extend your lifespan a long time into the future.
This is a perfect fit for what we do at Bioaccess®, Zach, because we can connect Dr. Andrews with countries and hospitals and investors in Latin America that do not want to wait seventeen years for this to be in the market, that we can accelerate the time to market for these technologies in the region. That’s why I’m still in conversation with Dr. Andrews. I’m still introducing him to potential partners in Latin America.
Now I’m starting to think about, too, what if you take someone like Dr. Andrews and give them a brain-computer interface, now you’re really speeding things up. When all of these really smart, amazing people that are doing these groundbreaking things have access to the world’s knowledge base. I was going to say fingertips, which is actually at their thought. I don’t even know how you say that, but at the speed of their thoughts, I mean, we’re going to have some amazing things happening very rapidly.
This is not that far in the future. Not far in the future. We’re already becoming super humans with Artificial Intelligence because it’s augmenting our capacity to analyze information, to think, to work. We are becoming superhumans slowly. Now, with this interface, the brain-computer interface is going to be even better.
How An AI-Powered Robot Dentist Did A Crown
Speaking of that, you mentioned a dentist, an AI-powered robot dentist that did a crown in just a few minutes. Could you tell us about that?
There’s a company out of Boston that came up with these innovation, perceptive technologies. One of the issues in dental work is that it’s very manual. It hasn’t really evolved in hundreds of years. We still do the same things manually that we used to do 100 years ago. I’ve been in this industry, Zach, for about twenty years, and we’ve done ophthalmology trials, neurology trials, orthopedic trials, cardiology trials, a little bit of everything, gene therapy trials, a little bit of everything.
I’ve never seen in twenty years of experience, as you said, in front sitting at these innovative technologies. I see startups every day. I speak with companies on a weekly basis. I probably speak with three different companies developing innovative technologies. I’ve never seen a dental device or a data innovation. Also, as a patient, I’ve been going to the dentist like you do for years and years, and it’s still the same thing. Nothing really changes.
It’s not very fun either.
Exactly. The innovation that you see is a little more comfortable, a little less painful, or shorter. Yes, anyway, the point is that this company is one topic. The other topic of conversation is that I’ve seen a lot of advancements in robotics and, of course, artificial intelligence, like any other industry. In my conversations with these startup companies, I see robotics more and more, artificial intelligence more and more, but I have never seen any advancement in dental products.
These companies’ perceptive technologies contacted us a couple of years ago, and they wanted to do a trial for their technology, and we were able to help them execute the trial. Newsweek picked it up because it’s really innovative. Nobody else has ever done anything like this to automate the process of doing dental work. Making the process very easy, simple, and straightforward for the dentist and also for the patient. It’s more predictable, less pain, faster, and so everybody wins.
How The Cyclotron Elevates Precision Medicine
I’m sure there are all kinds of other breakthroughs in robotics that are going to be speeding things up here as well. Can we talk a little bit about what you mentioned, the cyclotron, and is it Sierra Health, I believe so, this is early detection of chronic disease, is that right?
The topic, Zach, is precision medicine. That’s really the topic. The high-level topic of conversation. Precision medicine is a way to practice medicine in a more targeted way. For example, in oncology, for tumor treatments, you have limited options. You either have chemo or radiotherapy. Chemo is just you get something injected in your body, and the doctor hopes that it will kill the tumor before it kills you or your organs.
Radiotherapy is when you detect the tumor and then you apply some energy to the tumor, hoping that it will kill the tumor and it will have very minimal collateral damage in the healthy tissue. It’s impossible not to have collateral damage. It’s like throwing a bomb in a city. If you’re in the military world, if you want to kill one target, throwing a bomb, that guy is going to die. You need a drone. You need a more precise approach to kill that individual in military games. Precision medicine is just like that.
With new radiopharmaceutical advancements, we all now have the ability to find an isotope that binds to the cancer cells. You produce the isotope on a cyclotron production area, then ten minutes later, you take that material, you inject it into the patient, you put it through a PET scan machine, and you’re able to see specifically the cancer cells. You apply a therapy with another radiopharmaceutical material to kill. Essentially, it’s precision medicine at its highest.
Essentially, you’re only killing the cancer cells through this process and not the healthy cells. The isotope binds to the cancer cell, and then you can go in and say, “Kill that cell that has the isotope attached to it.”
Yes.
That’s on the cusp, that’s coming?
Yeah, that’s already approved. There are a couple of therapies approved by the FDA. There is also an application for Alzheimer’s disease, where you can stop Alzheimer’s disease because you can detect the amyloid plaque, and also apply the same principle.
This cancer and all that. Those are two of the scariest things for most people, probably is.
Also in cardiology. In cardiology right now, the application is more in the diagnostic side because with these advanced molecular imaging techniques combined with isotopes, you can do a more precise study on the heart and clearly detect where the blockages are, which are not usually visible on a regular X-ray machine in a cat lab.
Yes, I’ve had some of those tests, like the Cleerly test, if you’re familiar with that. It’s an advanced CT angiogram where they can look at the inside of your blood vessels and in your heart, the arteries, showing the exact amounts of plaque and where it is, and precision. Molecular imaging.
That’s a huge area of development. There are over 600 molecules of radiopharmaceuticals and theranostics. Radiopharmaceuticals are materials that are injected, and theranostics are an application of these radiopharmaceuticals. When you diagnose and you treat, if you combine these two approaches, they are called theranostic applications.
A cyclotron is a big machine that creates isotopes.
Big machine is a particle accelerator that you need to produce the isotopes, and then you need a radio pharmacy, which is a second component of the whole process.
These are going to be available to us in hospitals and places like that, basically, like a hospital, to buy one of these machines, and you could go there and have the precision treatment.
Yes. Cyclotrons are expensive. That’s why they are not so common. You need infrastructure, you need licensing. It’s a complex project to put a cyclotron production environment in a hospital, but eventually, they will become smaller, cheaper, and more efficient.
It sounds like that’s a cure essentially for cancer, Alzheimer’s, and heart disease. These top five killers in the world, heart disease, cancer.
Those three areas are heavily impacted by these innovations. Cardiology, oncology, and neurology.
Innovations To Expect In The Next Several Years
All of this is here now and will be very soon accessible. Just think about the few things we’ve talked about in this short conversation. I’m curious, because you have this front row seat and you see these things happening in real time, what is your expectation for your lifespan and your health span? What do you anticipate? All of this is only 5 to 10 years is what we’re talking about.
That’s a great question, Zach. I think we’re all going to live longer lives. It’s already happening. In the Middle Ages, the average lifespan of a person was 30 years or something like that.
It wasn’t even that long ago. 35 years.
It has progressed and progressed. You can also see the public policy. You see all these countries around the world trying to extend the retirement age because if you are 80 years old, you’re still productive. I have friends who are 80 years old, and they are as active as I am and as lucid and productive. There’s really no reason for us to stop at 65.
You’re just getting started.
Exactly. You have now more access to information and more access to knowledge who will make you a better human, and a more evolved human. You’re going to be able to reason better. I think living to a hundred is not going to be far. That’s not going to be something odd.
Living to a hundred well because you can lengthen your telomeres, and it’s a hundred thousand dollars now. I imagine 5 or 10 years from now, it’s going to be 10,000 or 5,000. It’ll be accessible to the average person. As long as we can just stay alive, stay healthy long enough for these advancements to become readily available. Exactly.
Imagine if you take this telomere lengthening therapy that we just discussed and you combine them with oncology. This is actually how we started with this company. We were not even talking about curing age, because aging wasn’t really a disease. The disease was the tumor, the cancer, or Alzheimer’s. What they did was to develop a protocol specific to certain diseases.
“Let’s analyze this. Let’s pick an indication of use. Let’s pick a disease that is common, where we can really make an impact.” They chose Alzheimer’s. We’re trying to understand if we lengthen the telomeres of an Alzheimer’s patient, we can cure Alzheimer’s. Now, if you have this new approach, then insurance companies and the government health care system will reimburse hospitals for this. It will be more accessible.
Julio’s Daily Healthy Habits
Once that happens, then the whole game shifts. It changes everything. Julio, this is exciting and fun. I know we’re probably just scratching the surface. Tell us maybe a little bit about your daily routines or habits. How do you keep yourself healthy? How do you keep yourself sharp? What’s a day in the life of Julio look like to stay healthy and sharp so that you can enjoy the benefits of some of these breakthroughs that are coming?
I have shifted my approach to longevity. I was more in the what is it that I can take and put inside my body to live longer? I did that for many years, and now I have realized that it’s the other way around. What is it that I’m thinking that will influence how long I will live? If you really think about it, if you eat lettuce and drink water and just have what people call healthy meals every day, but you are full of anger, guilt, and resentment.
I mean, I don’t think you’re going to live longer. On the other side, if I’m having ice cream, burgers, coke, all the bad stuff that we associate in society as bad, but you’re happy. Everybody loves you. You love everybody. You are free of guilt and anger. You forgive. You have a very good spiritual practice. I think you’re going to live longer than the guy who is eating lettuce and water.
Agreed, yeah. Why would you want to just extend your lifespan if you’re just unhappy and miserable? That’s not fun.
Exactly, yes. If you combine the two, that’s a winning combination.
If you have that positive, uplifting, optimistic mindset about the world, and I think in your seat, it’s probably impossible not to, because you’re seeing all these amazing things firsthand. The statistics show. Optimists live 15% longer than pessimists.
Exactly. That’s based on research. I have shifted my mindset, Zach. When I get involved with these trials, I’ve been in the war. We have implanted innovative technologies in patients that have changed their lives in fifteen minutes, and their families. Now my thinking is, if I get a new client, I’m so happy that I’m twenty patients under families. That country that is going to receive that income and that transfer of knowledge, that investigator, that hospital, it’s not about me buying a Mercedes or a Ferrari. I don’t care about it anymore. I care about how much impact I can have on humanity, on patients’ lives.
You’ve found your purpose and you’re living it. As you said, you’re making a difference for humanity in a significant way. I imagine that brings a ton of fulfillment and joy to your life daily.
I couldn’t care less about having a boat, having a convertible, I don’t care. Just have a peaceful life, loving life, forgiveness, and peace. Peace and love. That’s as simple as that.
Get In Touch With Julio
If this is the way you feel now, then why wouldn’t you want to extend that and continue to make an impact for humanity? Fantastic. Julio, this is really fun to talk with you. Your energy, your enthusiasm for life is tangible and palatable. Thank you for the amazing work that you’re doing to bring these cutting-edge and groundbreaking companies to fruition and make them accessible for us. It really is making a difference for humanity. Where can people find you? You have a podcast where you’re talking with all kinds of physicians and CEOs of companies and startups. Where can people find your podcast? Where can people connect with you, and how can they get started?
I’m very active on LinkedIn. People can look me up on LinkedIn or just Google. I’m very active in content production initiatives. As you said, I produce my podcast. It’s called the Global Trial Accelerators. We also have a newsletter called the Global Travel Accelerators newsletter. Our website is a source of information about what we do. BioaccessLA.com or just Google my name anywhere or on LinkedIn, Julio Martinez-Clark, or Bioaccess®, you’re going to find us.
Great. I’ll definitely be looking forward to your newsletter publications coming out and staying current. We’ll have to do this again, maybe six months or a year from now, to talk about what’s new on the horizon at that point.
This’ll be fun. We just got approval a couple of days ago for a new trial. It’s a company out of the UK that is developing this fascinating technology that came from Oxford University to repair nerve damage.
Fascinating. All these things that happen to us as we go through life, we can now have ways to fix them, right?
Yes.
This is so exciting. Thank you so much for taking the time to be with us, Julio. It’s really a privilege to have this conversation. Thank you for the work you’re doing.
Thank you for having me here.
My pleasure. Bye.
—
I hope that you’re excited as I am after that conversation about the future of health and of longevity. We’re just a few years away from these amazing breakthroughs. Within ten years, we’re going to have brain-computer interfaces where we can just think a thought and be connected to the world’s knowledge base and we’re going to be able to edit our genes to extend our lifespan significantly with some of these gene therapies that we talked about, Dr. Bill Andrews and Liz Parrish.
Maybe even going to the dentist, it’ll be a little more convenient and easier on us with these AI-empowered robots. If we have things like cancers or Alzheimer’s, there are treatments that are coming with these radio pharmacology and precision medicines where they can actually create the isotopes, link them to the cells that need to be treated, and then treat those cells directly without harming any of the healthy cells in our bodies.
This is happening. It’s here. It’s now. We live at such an exciting time, and I hope that you’ll have an optimistic outlook as much as Julio does. You can connect with him at BioaccessLA.com or just look him up on LinkedIn or listen to his podcast, Global Trial Accelerators, and sign up for his newsletter, as I’m going to do. Stay in touch. Thanks so much for joining on this episode. I hope that you, like I said, leave here feeling optimistic and remember that optimists live about 15% longer on average. Let’s have a great mindset, and we’ll see you next time here on the show.
